Rheumatoid Arthritis Drug Development Guidelines Reflect New Standards Of Care
Executive Summary
FDA’s new draft guidance seems to offer more flexibility on study duration, but it makes clear that trials lasting longer than 12 weeks should use an active comparator, not placebo.